109 results on '"Stilgenbauer, Stephan"'
Search Results
2. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
3. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
4. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
5. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
6. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
7. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
8. Supplementary Table S3 from Discovery of Candidate DNA Methylation Cancer Driver Genes
9. Supplementary Table S1 from Discovery of Candidate DNA Methylation Cancer Driver Genes
10. Data from Discovery of Candidate DNA Methylation Cancer Driver Genes
11. Supplementary Table S2 from Discovery of Candidate DNA Methylation Cancer Driver Genes
12. Supplementary Table S4 from Discovery of Candidate DNA Methylation Cancer Driver Genes
13. Data from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
14. Supplementary Table S3 from Discovery of Candidate DNA Methylation Cancer Driver Genes
15. Data from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
16. Supplementary Figures 1-10 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
17. Supplementary Table 2 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
18. Supplementary Table S5 from Discovery of Candidate DNA Methylation Cancer Driver Genes
19. Supplementary Table 1 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
20. Supplementary Table S2 from Discovery of Candidate DNA Methylation Cancer Driver Genes
21. Supplementary Table 2 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
22. Supplementary Table S6 from Discovery of Candidate DNA Methylation Cancer Driver Genes
23. Data from Discovery of Candidate DNA Methylation Cancer Driver Genes
24. Supplementary Figures 1-10 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
25. Supplementary Table S5 from Discovery of Candidate DNA Methylation Cancer Driver Genes
26. Supplementary Data from Discovery of Candidate DNA Methylation Cancer Driver Genes
27. Supplementary Table S1 from Discovery of Candidate DNA Methylation Cancer Driver Genes
28. Supplementary Table 1 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
29. Supplementary Data from Discovery of Candidate DNA Methylation Cancer Driver Genes
30. Supplementary Table S4 from Discovery of Candidate DNA Methylation Cancer Driver Genes
31. Supplementary Table S6 from Discovery of Candidate DNA Methylation Cancer Driver Genes
32. Table S3 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
33. Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
34. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
35. Table S1 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
36. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
37. Supplementary Figure 2A from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
38. Supplementary Figure 2C from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
39. Figure S3B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
40. Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
41. Figure S2A from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
42. Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
43. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
44. Table S2, Table S4, Table S6, Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Supplementary Methods from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
45. Table S6 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
46. Table S1 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
47. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
48. Supplementary Figure 1 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
49. Supplementary Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
50. Supplementary Figure 2B from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.